{
  "docId": "019de517-1302-72c9-b1b1-402f68725e8a",
  "docSlug": "8240d0b9060d59c07a4e5f5063c97322",
  "documentTitle": "Adagio Therapeutics | Results Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 11,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/4",
  "deckHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a",
  "deckJsonHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json",
  "deckAnchorHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.783,
        "x": 0.104,
        "y": 0.268
      },
      "kind": "list",
      "text": "Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d5ee62e-85db-410e-a941-ec2228591167",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.783,
        "x": 0.104,
        "y": 0.584
      },
      "kind": "list",
      "text": "Company aims to submit an application for Emergency Use Authorization (EUA) in the U.S. as soon as practicable",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7eb2a733-70ba-445d-9ab7-f978c399453d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.783,
        "x": 0.104,
        "y": 0.426
      },
      "kind": "list",
      "text": "Company expects to have initial CANOPY primary endpoint data by late 2023 or early Q1 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf588f85-57a9-42a5-8e4e-15b196652519",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.783,
        "x": 0.104,
        "y": 0.742
      },
      "kind": "list",
      "text": "Company continues to advance INVYMAB™, its proprietary platform approach designed for rapid, serial generation of new antibodies to address viral threats",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c33c760e-538f-4f4d-b8aa-c76205647f76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.076,
        "x": 0.86,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "INVIVYD",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2b4baf9-1ec5-4ccc-bfb8-0cdd7e526c82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.029,
        "w": 0.727,
        "x": 0.045,
        "y": 0.102
      },
      "kind": "title",
      "text": "RECENT BUSINESS HIGHLIGHTS & KEY ACHIEVEMENTS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2893cd74-a345-48c5-8609-c7483e59594d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "76117368-e337-4cf1-a65d-c3e6daecaeec",
      "evidence": "list/bullet: Company continues to advance INVYMAB™, its proprietary platform approach designed for rapid, serial generation of new antibodies to address viral threats",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}